Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Currently, insiders own just 63.63% of Vertex Inc (VERX)’s shares, while financial institutions hold 43.88%. Notable insider trades include Stamm John Richard, Director at Vertex Inc (VERX), who sold ...

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders ...

Deveron Corp. (TSXV: FARM) (“Deveron” or the “Company“), a leading agriculture services and data company in North America, ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.79% higher to $477.90 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, who's Executive Director of IR ... our Q2 results were very strong across ...

Celebrity event honoring supporters of Boston Arts Academy, Boston's only public high school for the visual and performing ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other biotech stocks. As we have mentioned in our article, “10 Best ...